ABSTRACT
Background Vectorcardiographic 3D QRS voltage-time integral (VTIQRS-3D) is a novel marker of ventricular dyssynchrony pertinent for cardiac resynchronization therapy. It may have additional clinical utility but its normal reference ranges have not been established. We sought to define reference ranges for VTIQRS-3D in healthy individuals.
Methods We retrospectively analyzed 12-lead ECGs of healthy adults (2010-2014) and compared them to patients with cardiomyopathy with reduced ejection fraction (EF) <50%. Using the Kors matrix, 12-lead ECGs with QRS duration ≤120 ms were converted to vectorcardiographic X, Y, and Z leads. VTIQRS-3D was calculated as the instantaneous root-mean-square (3D) voltage integrated over the QRS duration. Reference range limits were defined as the 2.5th to 97.5th percentiles respectively for healthy females and males in age groups 18-34, 35-54 and ≥55 years.
Results The study included 468 healthy adults (age 44.6 ± 17.0 years; 63.9% female) and 314 patients with cardiomyopathy (age 62.1 ± 14.0 years; 34.4% female). VTIQRS-3D was significantly larger in the cardiomyopathy patients compared to the healthy population (48.2±21.4 vs. 38.1±9.3 µVs, p<0.0001). Increased age and female sex were significant predictors of lower VTIQRS-3D in the healthy population (both p<0.0001). VTIQRS-3D reference ranges for respective age groups for healthy females were 23.2-55.0, 23.9-56.4 and 19.6-50.9 µVs, and for healthy males were 29.9-57.2, 28.2-56.7 and 21.4-55.9 µVs.
Conclusion VTIQRS-3D is higher at younger age in healthy population, male sex and in patients having cardiomyopathy with reduced EF. Age and sex need to be accounted for using VTIQRS-3D as a marker for structural heart disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by the NIH CTSA award # UL1TR002366
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Kansas gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos